HCV therapy has been transformed by the discovery of direct-acting antiviral medicines, which have led to better cure rates, shorter treatment durations, and greater tolerability. To assess the effectiveness and safety of DAAs in treating chronic HCV in patients with HIV and co-infection with chronic HCV infection exclusively, we conducted this research. 50 individuals with nave HCV infection who were also HIV-infected were studied at Abbasia Fever Hospital compared to 50 patients with HCV mono infection who were monitored for six months. In the course of a 12-week therapy with a combination of daclatasvir 90 mg and sofosbuvir 400mg+/- ribavirin 800mg daily, serial assessments of safety parameters, viral and immunological correlates, and adherence were made. CD4 T-lymphocyte count of 200 cells/mL or above was required for patients with HIV/HCV co-infection to be on antiretroviral treatment (ART). Conclusions and findings: HCV-HIV co-infected patients (48/50, 96%) had a strong sustained virological response (SVR) compared to HCV mono-infected patients (49/50, 98%). A substantial drop in the AST and ALT levels was seen at both the end of and 12 weeks following therapy in both groups. Otherwise, the haematological and biochemical values have not changed much. Sofosbuvir/daclatasvir was shown to be safe in patients with HIV/HCV co-infection, with the most prevalent side effects being tiredness (58 percent) and headache (42 percent), and no significant adverse events or drug-drug interactions with ART were recorded.